TY - JOUR
T1 - The insulin-like growth factor system as a target in breast cancer
AU - Yee, Douglas
PY - 1994/1/1
Y1 - 1994/1/1
N2 - Evidence from several experimental systems has shown that the insulin-like growth factors (IGFs) can stimulate breast cancer proliferation. Since IGF action is mediated by interaction with specific cell surface receptors, interruption of these signalling pathways could result in inhibition of cellular growth. In all extracellular fluids, the IGFs are associated with high affinity binding proteins, the IGFBPs. Although the function of each IGFBP is not known, it is clear that under certain circumstances the IGFBPs can bind the IGFs and prevent receptor activation, and thus might have a role in a targeted approach to breast cancer therapy. Here we present our studies using IGFBP-1 to inhibit growth of the breast cancer cell line MCF-7.
AB - Evidence from several experimental systems has shown that the insulin-like growth factors (IGFs) can stimulate breast cancer proliferation. Since IGF action is mediated by interaction with specific cell surface receptors, interruption of these signalling pathways could result in inhibition of cellular growth. In all extracellular fluids, the IGFs are associated with high affinity binding proteins, the IGFBPs. Although the function of each IGFBP is not known, it is clear that under certain circumstances the IGFBPs can bind the IGFs and prevent receptor activation, and thus might have a role in a targeted approach to breast cancer therapy. Here we present our studies using IGFBP-1 to inhibit growth of the breast cancer cell line MCF-7.
KW - IGF binding proteins
KW - IGF receptors
KW - MCF-7 breast cancer cells
KW - autocrine growth factors
KW - insulin-like growth factors
KW - targeted therapy
UR - http://www.scopus.com/inward/record.url?scp=0027942034&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027942034&partnerID=8YFLogxK
U2 - 10.1007/BF00666209
DO - 10.1007/BF00666209
M3 - Article
C2 - 7529598
AN - SCOPUS:0027942034
SN - 0167-6806
VL - 32
SP - 85
EP - 95
JO - Breast Cancer Research and Treatment
JF - Breast Cancer Research and Treatment
IS - 1
ER -